Conference Proceedings

Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Wei Xu, Shenmiao Yang, Constantine S Tam, John F Seymour, Keshu Zhou, Stephen Opat, Lugui Qiu, Mingyuan Sun, Tingyu Wang, Judith Trotman, Ling Pan, Sujun Gao, Jianfeng Zhou, Daobin Zhou, Jun Zhu, Yuqin Song, Jianda Hu, Ru Feng, Haiwen Huang, Zhiyue Huang Show all

Blood | American Society of Hematology | Published : 2020


Introduction Zanubrutinib is a highly specific, potent BTK inhibitor with minimal off-target inhibition of other kinases such as EGFR, JAK3, TEC and ITK. Zanubrutinib has shown 100% BTK occupancy, sustained over 24-hours, in both the peripheral blood and lymph node biopsies from patients treated at 160 mg twice daily and achieves durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (Tam 2019). In a phase 2 study conducted in patients with relapsed/refractory (R/R) CLL/SLL, treatment with zanubrutinib resulted in an overall response rate (ORR) of 85%. In addition, duration of response (DOR), progression free survival (PFS) and ove..

View full abstract